The company has said that the clinical trial successfully met all objectives and that BIO 300 was well tolerated at all dose levels which were studied. The completion of this trial is claimed to be an important milestone in further development of the drug.
Ronald Zenk, president and CEO of Humanetics, said: “Safety is the most important aspect in the development of any new drug. And since BIO 300 will likely be self-administered by civilians, we must be even more diligent in assuring the safety of this drug.”